Immunocore leverages its proprietary ImmTAX platform to develop T cell receptor (TCR) bispecific immunotherapies across oncology, infectious disease and autoimmune indications. The company’s pipeline includes five clinical-stage programs in oncology and infectious disease, advanced preclinical autoimmune programs and multiple earlier preclinical programs. Its most advanced candidate, tebentafusp (IMCgp100), has shown monotherapy activity in a Phase 2 trial in metastatic uveal melanoma and is being evaluated in an ongoing Phase 3 study. Immunocore collaborates with partners including Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and the Bill & Melinda Gates Foundation. Led by CEO Bahija Jallal, the company is based in Milton Park, Oxfordshire, U.K., and also has offices in Conshohocken, Pennsylvania and Rockville, Maryland. Proceeds from recent financings will be used to expand and accelerate its clinical-stage pipeline and to support potential commercial launch activities for tebentafusp. Immunocore is a clinical-stage T cell receptor biotechnology company developing and commercializing ImmTAX™ (Immune mobilising monoclonal TCRs) medicines for cancer, infection and autoimmune disease. Its lead program, tebentafusp (IMCgp100), is in pivotal clinical studies as a potential treatment for metastatic uveal melanoma. The oncology pipeline includes programs targeting MAGE-A4 (in collaboration with Genentech) and NYESO-1 (in collaboration with GlaxoSmithKline), and the company plans to advance two wholly owned clinical-stage programs for chronic Hepatitis B and PRAME. Immunocore also intends to accelerate development of its platform to treat autoimmunity, including work on type 1 diabetes in collaboration with the JDRF T1D Fund. Collaboration partners named in the articles include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and the Bill & Melinda Gates Foundation. The company is led by CEO Bahija Jallal, Ph.D., and has offices in Milton Park, Oxfordshire, UK and in Conshohocken, Pennsylvania and Rockville, Maryland in the US. Immunocore is described in the article as a British (UK) biotech company. The piece reports that Immunocore has secured a $40M investment from the Gates Foundation. It also says the company is in the final stages of assembling another "mega-raise." The article does not disclose the structure or instrument of the $40M investment. No operating metrics, past financing details, or founding year are provided in the source. Additional specifics in the original article are behind a paywall. Immunocore develops an immuno-oncology platform called ImmTACs (Immune mobilising mTCR Against Cancer), a suite of TCR-based biologic drugs intended to treat a broad range of solid tumours as monotherapies or in combination. The company plans to use the new financing to further accelerate its ImmTAC pipeline, with particular focus on advancing its lead proprietary program IMCgp100, which produced positive Phase I/IIa trial data in April 2015 in metastatic cutaneous and ocular melanoma. Immunocore also delivers on partnerships with Genentech, GlaxoSmithKline and MedImmune (the biologics division of AstraZeneca) while progressing its internal programs. Founded in 2008 out of Oxford University and led by CEO Dr. Eliot Forster, the company is based in Oxon, UK and has more than 155 staff. The announcement frames the financing as supporting both pipeline advancement and existing collaborations.

Total raised

$665M

Funding rounds

5

Latest round

Series C

Latest activity

Jan 2021